3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
2
Recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
CNS
2
Conditions
Glioma
3
Glioblastoma
3
Neuroectodermal Tumors
2
Nervous System Diseases
2
Neoplasms, Neuroepithelial
2
Neoplasms, Nerve Tissue
2
Gliosarcoma
2
Brain Neoplasms
2
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Neoplasms
1
Disease
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Interventions
Temozolomide
94
Radiotherapy
59
Bevacizumab
59
Radiosurgery
41
Carboplatin
27
Irinotecan
26
Magnetic Resonance Spectroscopy
25
Surgical Procedures, Operative
23
Etoposide
22
Carmustine
20
Filgrastim
18
Erlotinib Hydrochloride
17
Cyclophosphamide
16
Cisplatin
16
Vincristine
15
Lomustine
15
Lapatinib
15
Sorafenib
13
Radiation
13
Trastuzumab
12
Nivolumab
12
Imatinib Mesylate
12
Thalidomide
11
Surveys and Questionnaires
11
Granulocyte Colony-Stimulating Factor
11
Radiotherapy, Intensity-Modulated
10
Aminolevulinic Acid
10
temsirolimus
9
Topotecan
9
Thiotepa
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Brain Neoplasms
×
Oncolytic Virotherapy
×
Clear all
NCT02798406
2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2
Completed
49 enrolled
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled